TERAPI3.: Protection of Intellectual Property rights of new therapeutic agents against amyloid transthyretin diseases: AT09 technology. (Q2866989)

From EU Knowledge Graph
Revision as of 13:37, 21 October 2021 by DG Regio (talk | contribs) (‎Removed claim: budget (P474): 25,000.0 euro)
Jump to navigation Jump to search
Project Q2866989 in Portugal
Language Label Description Also known as
English
TERAPI3.: Protection of Intellectual Property rights of new therapeutic agents against amyloid transthyretin diseases: AT09 technology.
Project Q2866989 in Portugal

    Statements

    0 references
    15 December 2017
    0 references
    14 December 2020
    0 references
    BSIM THERAPEUTICS, S.A.
    0 references
    Q2988326 (Deleted Item)
    0 references

    40°21'55.76"N, 8°39'29.95"W
    0 references
    O projeto TERAPI3 visa a proteção dos direitos de Propriedade Intelectual de uma nova classe de agentes terapêuticos contra doenças raras, nomeadamente doenças amiloides de transtirretina. Estes novos compostos são pequenas moléculas pertencentes à série química AT09 desenvolvida pela BSIM2. (Portuguese)
    0 references
    The TERAPI3 project aims to protect the intellectual property rights of a new class of therapeutic agents against rare diseases, namely transthyretin amyloid diseases. These new compounds are small molecules belonging to the AT09 chemical series developed by BSIM2. (English)
    7 July 2021
    0 references
    Cantanhede
    0 references

    Identifiers

    CENTRO-01-0247-FEDER-037867
    0 references